

POLICY NAME

Apomorphine Hydrochloride (apomorphine HCL)

POLICY #

1072P

Criteria

Treatment of Parkinson's Disease

- ☐ 1.1 Current treatment with at least one anti-Parkinson's agent
- ☐ 1.2 Hypomobility "off" episodes or unpredictable on/off episodes
- ☐ 1.3 Documented failure of levodopa dose modification such as shortening of dosing interval
- ☐ 1.4 Documented failure, intolerance, or contraindication to a dopamine agonist such as pramipexole, ropinirole
- ☐ 1.5 Documented failure, intolerance, or contraindication to the use of a catechol-O-methyltransferase inhibitor such as entacapone or tolcapone
- ☐ 1.6 Documented failure, intolerance, or contraindication to the use of a monoamine oxidase-B inhibitor such as rasagiline or selegiline
- ☐ 1.7 Documentation indicating Apokyn will NOT be used concomitantly with a 5HT3 antagonist such as ondansetron